CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical firm dedicated to growing novel therapies with the potential to rework the lives of individuals with debilitating problems of the mind, right this moment introduced it would host the primary Sage Science Highlight webcast centered on an in-depth evaluate of SAGE-718.
Sage will present particulars on its progress with SAGE-718, the corporate’s lead neuropsychiatry product candidate being explored for the potential remedy of cognitive problems related to NMDA receptor dysfunction, together with Huntington’s illness, Alzheimer’s illness, and Parkinson’s illness. Sage may also share further particulars on the just lately introduced knowledge from the PARADIGM Research of SAGE-718 in sufferers with gentle cognitive impairment attributable to Parkinson’s illness and the deliberate initiation of a Section 2 placebo-controlled examine in Huntington’s illness. Moreover, the Firm will talk about the unmet want in Huntington’s illness, with participation and views from a number one neurologist and a affected person advocate.
The Sage Science Highlight is a brand new webcast sequence designed to take a deeper have a look at Sage’s work in mind well being. It would complement Sage’s annual FutureCast occasion, which gives an replace on the corporate’s general analysis and improvement technique and scientific progress in its key melancholy, neurology and neuropsychiatry franchise applications.
Audio system on the Might 20th webcast will embrace:
- Jim Doherty, Chief Analysis Officer, Sage Therapeutics
- Mike Quirk, Vice President, Pharmacology, Sage Therapeutics
- Aaron Koenig, Govt Medical Director, Early Growth, Sage Therapeutics
- Dr. Samuel Frank, Affiliate Professor of Neurology, Beth Israel Deaconess Medical Heart
- Seth Rotberg, Affected person Advocate (Huntington’s Illness)
The webcast could be accessed on the investor web page of Sage’s web site at investor.sagerx.com. A replay of the webcast can be accessible roughly two hours after the completion of the occasion.
About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical firm dedicated to growing novel therapies with the potential to rework the lives of individuals with debilitating problems of the mind. We’re pursuing new pathways with the purpose of enhancing mind well being, and our melancholy, neurology and neuropsychiatry franchise applications intention to alter how mind problems are considered and handled. Our mission is to make medicines that matter so folks can get higher, sooner. For extra info, please go to www.sagerx.com.
Varied statements on this launch concern Sage’s future expectations, plans and prospects, together with with out limitation: statements relating to our deliberate analysis and improvement actions and the chance to assist sufferers in varied indications. These statements represent forward-looking statements as that time period is outlined within the Personal Securities Litigation Reform Act of 1995. These forward-looking statements are neither guarantees nor ensures of future efficiency, and are topic to quite a lot of dangers and uncertainties, a lot of that are past our management, which may trigger precise outcomes to vary materially from these contemplated in these forward-looking statements, together with the dangers that: we might encounter hurdles and delays in initiation, conduct or completion of our deliberate scientific trials, together with on account of slower than anticipated web site initiation or enrollment; selections or actions of the FDA might have an effect on the initiation and timing of scientific trials and our skill to proceed with additional improvement; ongoing and future non-clinical and scientific outcomes might not meet their main or key secondary endpoints or help additional improvement; we might encounter adversarial occasions at any stage of improvement that negatively impression additional improvement or that require further nonclinical and scientific work which can not yield optimistic outcomes; and we might encounter technical and different sudden hurdles within the improvement and manufacture of our product candidates which can delay our timing or change our plans, or in any other case negatively impression our enterprise; in addition to these dangers extra totally mentioned within the part entitled “Threat Elements” in our most up-to-date Quarterly Report on Type 10-Q, in addition to discussions of potential dangers, uncertainties, and different essential components in our subsequent filings with the Securities and Change Fee. As well as, any forward-looking statements characterize our views solely as of right this moment, and shouldn’t be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to replace any forward-looking statements.